SNX-111 neuron-specific calcium channel blocker: The FDA has placed a hold on a Phase II trial in 50 patients due to reports of recumbent hypotension

The company said the condition is not unexpected in severely traumatized patients, although it did not appear in the healthy volunteers in a Phase I trial.

NXCO said clinicians can treat the lowered blood pressure and want to continue the trial because they are seeing unexpected improvements in Glasgow coma scores. ...